|  | | |  | Information Booklet |
A booklet produced by Leukaemia Research Fund giving background information on clinical trials is available to download.
Text version of the booklet
| Registers of Trials |
Current Controlled Trials
International Cancer Research Portfolio - a register of UK and US cancer research (including trials)
Last updated 06/02/2006
| Leukaemia Research sponsored trials |
| A randomized trial for patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome aged 60 or over | | Trial Code: | 62207270 | | Type: | Phase III | | Status: | Not Stated | | Link: | http://www.controlled-trials.com/isrctn/trial/ACUT... | Patients will be randomised between intensive and non-intensive chemotherapy at diagnosis.
Those in the intensive treatment arm will be randomised between 50 mg/m2/day Daunorubicin versus 35 mg/m2/day Daunorubicin and 200 mg/m2/day Ara-C versus 400 mg/m2/day.
Patients in the lower dose Daunorubicin arm will be further randomised between PSC833 versus control, ie no PSC833.
After three courses of treatment, patients in the intensive arm will be randomised between short (three courses) versus long (four courses) consolidation therapy.
Patients in the non-intensive arm will be randomised between hydroxyurea and low-dose Ara-C and 45 mg/m2/day All-trans retinoic acid versus no retinoic acid. |
| WT1 peptide vaccination for leukaemia - a phase I/II pilot study | | Type: | Phase I/II | | Status: | Not Stated | | The aim of this trial is to use a vaccine that stimulates an immune response against malignant blood cells that display the Wilms tumour antigen-1 (WT1). High levels of WT1 are usually produced by leukaemia cells in patients with acute or chronic myeloid leukaemia and patients with myelodysplastic syndrome (MDS). Although treatments for this group of patients are available, WT1 vaccination may offer a better alternative to the currently available treatments. |
| Phase II study of the tolarability of the histone deacetylase inhibitor sodium valproate in conjunction with ATRA (all trans retinoic acid) in patients with acute myeloid leukaemia | | Type: | Phase II | | Status: | Not Stated | | Acute myeloid leukaemia is very difficult to cure in the majority of adults, therefore new promising treatments are urgently required. Cells of all types of acute myeloid leukaemia present characteristic gene abnormalities associated with structural perturbations. Hence, substances like sodium valproate that can act as modulators of the gene structure are thought to be of therapeutic benefit. Sodium valproate is widely used in the treatment of epilepsy and as a mood stabiliser and has shown promising results in killing leukaemia and other tumour cells. The use of this drug in conjunction with differentiation agents is thought to benefit all patients with acute myeloid leukaemia, even those who become resistant to treatment with a differentiation agent alone. |
Last updated 06/02/2006
| Non-Leukaemia Research sponsored trials |
Acute Myeloid Leukaemia Trial 12 (modified) for patients aged under 60
| | Trial Code: | 55678797 | | Type: | Phase III | | Status: | Not Stated | | Link: | http://www.controlled-trials.com/isrctn/trial/ACUT... | Four randomised comparisons:
At diagnosis:
1. S-DAT versus H-DAT
2. All-trans-retinoic acid (ATRA) versus not (except for APL patients who will receive ATRA)
After course 3:
3. 4 versus 5 courses of total therapy
4. BMT versus chemotherapy as the final course of therapy |
| AML 15 - A trial of directed therapy in younger patients with Acute Myeloid Leukaemia | | Trial Code: | 17161961 | | Type: | Phase III | | Status: | Open | | Link: | http://www.controlled-trials.com/mrct/trial/ISRCTN... | For patients with acute myeloid leukaemia (AML) the aims of the AML15 trial are:
1. To compare two induction schedules (namely DAT and FLAG-Ida).
2. To assess the value of Mylotarg during induction
3. To compare the standard MRC consolidation chemotherapy (ie. MACE + MidAC) versus high-dose Ara-C
For patients with APL:
1. To compare the MRC approach (i.e. four courses of intensive chemotherapy) with the Spanish approach (based on anthracyclines with maintenance therapy).
2. To assess the value of Mylotarg during consolidation (i.e. with course 3) |
Last updated 06/02/2006 |
|
|
|
